Join Us

We are 217,583 members in 84 forums discussing 160,638 topics.

Help with Abbreviations

Topic: Aspirin help for some BC survivors, hurt for some

Forum: Clinical Trials, Research News, Podcasts, and Study Results —

Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: Aug 12, 2019 02:20PM

wallycat wrote:

https://www.sciencedaily.com/releases/2019/08/1908...

This is probably why we can all do the same thing and have such different outcomes.

Dx 4/07 1 month before turning 50; ILC 1.8cm, ER+/PR+, HER2 neg., Stage 1, Grade 2, 0/5 nodes. Onco score 20, Bilateral Mast., tamoxifen 3-1/2 years, arimidex-completed 4/20/2012
Log in to post a reply

Page 1 of 1 (3 results)

Posts 1 - 3 (3 total)

Log in to post a reply

Aug 13, 2019 01:07PM Jelson wrote:

Would people know if they have "a methylated tumor promotor of breast cancer gene 1, known as BRCA1"? Is this a fancy way of saying you have the BRCA1 gene or is it a sub-type and if so, is it info that those who have had genetic testing for BRCA would be routinely given? If this info is not now supplied, it should be so people can make informed decisions about taking aspirin whether to prevent breast cancer or stroke.

Dx 4/17/2009, DCIS, <1cm, Stage 0, Grade 3, 0/0 nodes, ER+/PR+
Log in to post a reply

Aug 13, 2019 08:24PM wallycat wrote:

Jelson, I agree. I don't think they know enough about the implications. I wonder how many other gene mutations affect drug outcomes and just too many to decipher or corral at this point. Early days it seems.

Dx 4/07 1 month before turning 50; ILC 1.8cm, ER+/PR+, HER2 neg., Stage 1, Grade 2, 0/5 nodes. Onco score 20, Bilateral Mast., tamoxifen 3-1/2 years, arimidex-completed 4/20/2012
Log in to post a reply

Aug 14, 2019 02:22PM Murfy wrote:

I wasn't able to access the original paper and this 'blurb' just didn't provide us enough info.

I WAS bummed that apparently PR+ is necessary for aspirin to an effective BC preventative!

Dx at 62: Oncotype=52; Path (ER=99%, PR=0%, Ki67=55%) Dx 10/2017, DCIS/IDC, Left, 1cm, Stage IA, Grade 3, 0/5 nodes, ER+/PR-, HER2- Surgery 11/14/2017 Mastectomy: Left Chemotherapy 1/13/2018 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Hormonal Therapy 3/31/2018 Aromasin (exemestane)

Page 1 of 1 (3 results)